tuneTypical Dose
1.0–3.0 g
Amino Acid
Tryptophan
L-Tryptophan
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Latency effects may appear after several treatment nights. Mood shifts, if present, are usually within 2-8 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Tryptophan is an essential amino acid and precursor to serotonin and melatonin. It is used for sleep quality and mood-related goals, particularly when dietary intake or serotonin synthesis is constrained.
Studies suggest improved sleep onset and sleep quality, likely through increased melatonin synthesis and serotonin-mediated sleep regulation. Mood effects are modest and more likely in susceptible individuals or low intake states. Minority evidence includes benefits for PMS symptoms and seasonal mood patterns. Effects depend on dietary amino acid competition and individual serotonin metabolism, so outcomes vary.
L-tryptophan is a serotonin precursor. Pooled data suggest limited sleep-onset benefit in specific contexts and inconsistent clinical mood effects.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced sleep onset latency in selected insomnia adults after repeated bedtime dosing (1-3 g).
Secondary Outcomes
- Modest, inconsistent self-reported mood/anxiety improvements in some healthy adult studies. No reliable antidepressant signal in at least one clinical trial.
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- High-risk comorbid disease
Side effects
- Drowsiness
- Nausea
- Headache
- Lightheadedness
Interactions
- Uncertain
Avoid if
- Active malignancy
- Unstable cardiovascular or psychiatric disease
Evidence
Study-level References
tryptophan-SRC-001Randomized, placebo-controlled sleep study
Sourceopen_in_newPMID: 227180
Population: Adults with sleep-onset insomnia
Dose protocol: 1 g and 3 g at bedtime, repeated-night protocol
Key findings: Sleep onset latency improved on selected nights at 3 g. 1 g was less reliable across nights.
Notes: Small sample and older protocol with adaptation effects.
Paper content
Sleep onset latency improved on selected nights at 3 g; 1 g was less reliable across nights.
tryptophan-SRC-002Randomized, double-blind sleep trial
Sourceopen_in_newPMID: 3097693, DOI: 10.1007/BF00181230
Population: Chronic sleep-onset insomniacs
Dose protocol: 3 g/day for 3–6 nights in one arm
Key findings: Delayed onset of effect with significant latency reduction on nights 4–6, supporting repeated-dose and timing dependence.
Notes: Small, older sample, historical endpoints.
Paper content
Delayed onset of effect with significant latency reduction on nights 4–6, supporting repeated-dose and timing dependence.
tryptophan-SRC-003Systematic review of RCTs
Sourceopen_in_newPMID: 32272859, DOI: 10.1080/19390211.2020.1746725
Population: Healthy adults
Dose protocol: 0.14–3 g/day across included studies
Key findings: Mixed but directionally positive effects on negative affect and positive mood in subset of RCTs. Inconsistent aggression/depression effects.
Notes: Heterogeneous designs, small effect sizes, population restriction to healthy individuals.
Paper content
Mixed but directionally positive effects on negative affect and positive mood in subset of RCTs; inconsistent aggression/depression effects.
tryptophan-SRC-004Double-blind, placebo-controlled trial
Sourceopen_in_newPMID: 7407745, DOI: 10.1177/070674378002500507
Population: Elderly adults with depressive symptoms
Dose protocol: 6 g/day for 6 weeks
Key findings: No statistically significant advantage of L-tryptophan over placebo on depression measures.
Notes: Older small RCT, single-site clinical context.
Paper content
No statistically significant advantage of L-tryptophan over placebo on depression measures.
tryptophan-SRC-005Retrospective cohort + nested case-control
Sourceopen_in_newPMID: 1727200, DOI: 10.1001/jama.267.1.77
Population: Exposed supplement users and matched controls
Dose protocol: Use history context, contamination period and brand/lot-linked cluster signal
Key findings: EMS risk was strongly associated with products from one manufacturer and dose-dependent risk among high-dose users in that cohort.
Notes: Historical outbreak context. Does not establish intrinsic toxicity of pure unadulterated modern products.
Paper content
EMS risk was strongly associated with products from one manufacturer and dose-dependent risk among high-dose users in that cohort.
tryptophan-SRC-006Randomized, double-blind, placebo-controlled crossover trial
Sourceopen_in_newRueda GH, Causada-Calo N, Borojevic R, et al. Oral tryptophan activates duodenal aryl hydrocarbon receptor in healthy subjects: a crossover randomized controlled trial. Am J Physiol Gastrointest Liver Physiol. 2024;326(6):G687-G696. doi:10.1152/ajpgi.00306.2023. PMID:38591144.
Population: Healthy adult subjects.
Dose protocol: L-tryptophan 3 g/day for 3 weeks, crossover design.
Key findings: Oral tryptophan activated duodenal aryl hydrocarbon receptor and induced microbial indole and host kynurenine pathways in healthy adults without adverse effects.
Notes: Mechanistic human study. Confirms gut-level biological activity of supplemental tryptophan and expands evidence beyond sleep and mood endpoints.
Paper content
This double-blind crossover trial randomized 20 healthy adults to 3 weeks of oral L-tryptophan 3 g/day or placebo on a low-tryptophan diet, with a 2-week washout before crossing over. Tryptophan did not change gastrointestinal or psychological symptom scores, but it increased AhR activation capacity in duodenal contents and raised urinary and plasma kynurenine and indole metabolites. The fecal microbiome shifted only modestly and monocyte cytokine production did not change. This makes the study a useful biological-activity anchor rather than a symptom-efficacy trial: it shows that supplemental tryptophan reaches relevant gut-immune pathways in humans, but it does not modernize sleep or mood claims directly.